Abstract Submission
I. Submission Period
It opens from April 1 until July 31, 2026 for the regular abstract, and September 15, 2026 for the late-breaking abstract.
II. Abstract Type
Regular Abstract
All types of gynecologic oncology-related research are eligible for submission. The abstract should address scientific questions, detail clinical observations, or contain primary scientific data. Abstracts of clinically related subjects should be combined into a single abstract. Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts. Case reports are not accepted.
Late-Breaking Abstract Placeholder
Eligible submissions include randomized phase II and phase III clinical research trials that will have an impact on practice for which no preliminary data are available at the time of the abstract submission deadline (July 31, 2026). ASGO will also consider other original research studies that are high impact with practice-changing implications for which no preliminary data are available.
III. General Guidelines for Submission
- Originality: Abstracts must be original and must not be or have been published or presented at any other meeting prior to ASGO 2026.
- Submission Method: Abstracts must be submitted online via the website and indicate whether the abstract is for Oral, Poster, Surgical Video Presentation, and Young Doctor Session. Authors who do not wish to be considered for oral presentation are requested to indicate this when submitting. However, please note that the Scientific Committee will make the final decision for the type of presentation.
- Submitter: Only the first author can submit an abstract.
- Author Registration: Author(s) of accepted abstracts must register ASGO 2026.
- Ethical Statement: Provide information on ethical committee approval and informed consent types for clinical research. The names and initials of patients or volunteers should not be used.
- Publication: Selected abstracts will be published in the conference book.
IV. Presentation Type
Indicate whether the abstract is for:
- Oral Presentation
- Poster Presentation
- Surgical Video Presentation
- Young Doctor Session
V. Abstracts Format
- Title: Limited to 25 words. Capitalize the first letter. However, do not capitalize article words such as "a," "the," "and," & "of" unless the article is the first word of the title. Abbreviations are not allowed in the title.
- Structure: All abstracts must contain the following sections: Introduction, Materials & Methods, Results, and Conclusion/Implications.
- Word Count: Abstracts should be no more than 400 words. Tables or figures are not allowed.
- Language & Format: All abstracts must be submitted and presented in English (American usage only). In terms of writing numbers and decimals, use decimal points (.) not commas (,).
VI. Presentation Specifications for Regular Abstracts
Oral Presentation
- Duration: 5 mins presentation + 3 mins Q&A.
- Slides: Must include a conflict of interest disclosure slide.
Poster Presentation
- Format: Should be printed; e-posters are not accepted.
- Poster mounting area: H 180 cm × W 90 cm.
- To be provided by presenter: A slip (H 20 cm × W 70 cm) with title, name(s) of author(s), and affiliation(s).
- Provided by the secretariat: Poster number (20 cm × 20 cm), pins along with a panel.
Surgical Film Presentation
- Duration: 7-minute well-edited video.
- Content: Must include a title page and narratives.
Young Doctor Session
- Oral Presentation: 8 minutes each, followed by a discussion after every 3-4 presenters.
- Graphics Presentation: 6 minutes each with templates to follow, followed by a discussion at the end.
VII. Abstract Acceptance
- The Scientific Committee of ASGO 2026 reserves the rights to make the final decision of presentation categories and acceptance/rejection of abstract.
- Notification of acceptance will be sent to the first author by email before September 30, 2026.
VIII. Submission Topics (17 topics)
- 1. Cervical cancer
- 2. Endometrial cancer
- 3. Ovarian cancer
- 4. Vaginal and vulvar cancer
- 5. Trophoblastic diseases
- 6. Rare gynecological cancers
- 7. Screening/early detection
- 8. Symptom management/supportive cancer care
- 9. Palliative care & quality of life after treatment of gynecologic cancer
- 10. Non-invasive disease of gynecologic cancer (pre-cancer)
- 11. Translational research & basic science
- 12. Surgical techniques (minimally invasive surgery, new methods...)
- 13. Novel therapy (immunotherapy, ADC, cell therapy)
- 14. Genetics: genomic, biomarker or prognostic marker
- 15. Artificial intelligence (Al), database
- 16. Imaging for gynecologic malignancies
- 17. Social inequities and impact on cancer outcomes
IX. Contact Information
For any further information related to abstract submission, please contact Secretariat by e-mail.
Secretariat:
Zhuozhen Sun (She/Her): sun.zhuozhen@zs-hospital.sh.cn
Jiawen Kenny Wang (He/Him): apollo10-asgo2026@fumed.com.cn